Page last updated: 2024-08-21

indazoles and ixazomib

indazoles has been researched along with ixazomib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Broaddus, R; Fu, S; Hess, K; Hong, D; Janku, F; Karp, D; Kopetz, S; Liu, L; Naing, A; Overman, M; Piha-Paul, S; Shi, N; Subbiah, V; Tsimberidou, AM; Wang, Y; Yao, J	1

Trials

1 trial(s) available for indazoles and ixazomib

Article	Year
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports, 2020, 02-20, Volume: 10, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult	2020

Article

Year

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.

Scientific reports, 2020, 02-20, Volume: 10, Issue:1

Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult

2020